Wallace J L
Intestinal Disease Research Unit, Faculty of Medicine, University of Calgary, Alberta.
Can J Gastroenterol. 1996 Nov-Dec;10(7):451-9. doi: 10.1155/1996/850710.
The toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs) in the gastrointestinal tract continues to be a major limitation to their use in the treatment of inflammatory disorders. Better understanding of the pathogenesis of NSAID enteropathy has facilitated the development of novel NSAIDs that spare the gastrointestinal tract. In particular, identification and characterization of the inducible form of prostaglandin synthase has led to the design of novel NSAIDs that specifically target that enzyme. The pathogenesis of NSAID gastroenteropathy is reviewed, as are the strategies that have been used in the past and are used now to develop NSAIDs that spare the gastrointestinal tract. Also reviewed are the strategies being employed to achieve this goal in the future.
非甾体抗炎药（NSAIDs）在胃肠道的毒性仍然是其用于治疗炎症性疾病的主要限制因素。对NSAID肠病发病机制的深入了解推动了新型NSAIDs的开发，这些新型NSAIDs对胃肠道具有保护作用。特别是，诱导型前列腺素合酶的鉴定和表征促使了新型NSAIDs的设计，这些药物能特异性地作用于该酶。本文综述了NSAID胃肠病的发病机制，以及过去和现在用于开发保护胃肠道的NSAIDs的策略。同时也对未来为实现这一目标所采用的策略进行了综述。
